1897 related articles for article (PubMed ID: 26597926)
21. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
23. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
Matchar DB; McCrory DC; Orlando LA; Patel MR; Patel UD; Patwardhan MB; Powers B; Samsa GP; Gray RN
Ann Intern Med; 2008 Jan; 148(1):16-29. PubMed ID: 17984484
[TBL] [Abstract][Full Text] [Related]
24. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
25. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
28. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
Ueda S
J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
30. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
31. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
Hiremath S; Fergusson DA; Fergusson N; Bennett A; Knoll GA
Am J Kidney Dis; 2017 Jan; 69(1):78-86. PubMed ID: 27712852
[TBL] [Abstract][Full Text] [Related]
32. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
; Lawler PR; Derde LPG; van de Veerdonk FL; McVerry BJ; Huang DT; Berry LR; Lorenzi E; van Kimmenade R; Gommans F; Vaduganathan M; Leaf DE; Baron RM; Kim EY; Frankfurter C; Epelman S; Kwan Y; Grieve R; O'Neill S; Sadique Z; Puskarich M; Marshall JC; Higgins AM; Mouncey PR; Rowan KM; Al-Beidh F; Annane D; Arabi YM; Au C; Beane A; van Bentum-Puijk W; Bonten MJM; Bradbury CA; Brunkhorst FM; Burrell A; Buzgau A; Buxton M; Cecconi M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Ezekowitz J; Fitzgerald M; Gattas D; Godoy LC; Goossens H; Haniffa R; Harrison DA; Hills T; Horvat CM; Ichihara N; Lamontagne F; Linstrum KM; McAuley DF; McGlothlin A; McGuinness SP; McQuilten Z; Murthy S; Nichol AD; Owen DRJ; Parke RL; Parker JC; Pollock KM; Reyes LF; Saito H; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Singh V; Turgeon AF; Turner AM; Zarychanski R; Green C; Lewis RJ; Angus DC; Berry S; Gordon AC; McArthur CJ; Webb SA
JAMA; 2023 Apr; 329(14):1183-1196. PubMed ID: 37039790
[TBL] [Abstract][Full Text] [Related]
33. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.
Wang B; Wang F; Zhang Y; Zhao SH; Zhao WJ; Yan SL; Wang YG
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):263-74. PubMed ID: 25660574
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
35. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
[TBL] [Abstract][Full Text] [Related]
37. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ
Lancet; 2005 Dec; 366(9502):2026-33. PubMed ID: 16338452
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.
Lee VC; Rhew DC; Dylan M; Badamgarav E; Braunstein GD; Weingarten SR
Ann Intern Med; 2004 Nov; 141(9):693-704. PubMed ID: 15520426
[TBL] [Abstract][Full Text] [Related]
40. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
